Landmark Study Shows Once-Monthly Long-Acting Therapy INVEGAÂ® SUSTENNAÂ® (paliperidone palmitate) Significantly Delayed Time to Relapse in Patients with Schizophrenia Compared to Daily Oral Antipsychotics